Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00604409 · ClinicalTrials.gov registry record · Phase 1
Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00604409 is a Phase 1 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 34 participants.
The verdict
NCT00604409, a Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This trial is testing the safety of combining the oral chemotherapy drug capecitabine with radio-labeled microspheres injected directly into the liver.
Interventions
- DRUG capecitabine
- RADIATION SIRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2006-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00604409
The ClinicalTrials.gov registry entry for NCT00604409 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which capecitabine is the first listed.
NCT00604409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00604409 about?
NCT00604409 is a clinical study titled "Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer". This trial is testing the safety of combining the oral chemotherapy drug capecitabine with radio-labeled microspheres injected directly into the liver.
What is the current status of trial NCT00604409?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2006-04. Estimated completion is 2015-01.
What interventions are being tested in trial NCT00604409?
The interventions under investigation include: capecitabine (DRUG), SIRT (RADIATION).
Who is sponsoring clinical trial NCT00604409?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.